Candel Therapeutics, Inc. entered into a new employment agreement with Chief Financial Officer Charles Schoch on June 12, 2026. The agreement provides for an annual base salary of $468,600 and a target annual bonus of 40% of his base salary, along with severance-related benefits and equity acceleration in the event of a change in control. Candel Therapeutics, Inc. is a biotechnology company focused on developing oncology-related therapies.